InMed Pharmaceuticals Inc Share Price Deutsche Boerse AG
Equities
CA13764X1069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
14/05 | Earnings Flash (INM) INMED PHARMACEUTICALS Posts Q3 Revenue $1.2M | MT |
14/05 | InMed Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
Sales 2024 * | 72.98L 53.56L 49.37L 45Cr | Sales 2025 * | 91.23L 66.94L 61.72L 56Cr | Capitalization | 25.54L 18.74L 17.28L 16Cr |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 0.35 x |
Net cash position 2024 * | - 0 0 0 | Net cash position 2025 * | - 0 0 0 | EV / Sales 2025 * | 0.28 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.01% |
Latest transcript on InMed Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Eric Adams
CEO | Chief Executive Officer | 61 | 16/16/16 |
Chief Operating Officer | - | 05/18/05 | |
Colin Clancy
IRC | Investor Relations Contact | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Janet Grove
BRD | Director/Board Member | 57 | 11/22/11 |
Eric Adams
CEO | Chief Executive Officer | 61 | 16/16/16 |
Andrew Hull
CHM | Chairman | 61 | 12/16/12 |
1st Jan change | Capi. | |
---|---|---|
+11.60% | 11TCr | |
-4.68% | 2.43TCr | |
-0.82% | 2.2TCr | |
-10.12% | 1.82TCr | |
-42.12% | 1.64TCr | |
-17.47% | 1.56TCr | |
+2.77% | 1.36TCr | |
+34.58% | 1.23TCr | |
+77.64% | 887.31Cr |